Cincinnati Wellness Review: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Cincinnati Wellness Review.

December 2025

Mo	Tu	We	Th	Fr	Sa	Su
1	2	3	4	5	6	7
8	9	10	11	12	13	14
15	16	17	18	19	20	21
22	23	24	25	26	27	28
29	30	31

January 2026

Mo	Tu	We	Th	Fr	Sa	Su
			1	2	3	4
5	6	7	8	9	10	11
12	13	14	15	16	17	18
19	20	21	22	23	24	25
26	27	28	29	30	31

February 2026

Mo	Tu	We	Th	Fr	Sa	Su
						1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28

Press releases published on December 3, 2025

Dec. 3, 2025

Mesoblast Participation at Piper Sandler Conference

GlobeNewswire

Dec. 3, 2025

Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® (lecanemab-irmb) Maintenance Treatment in Early Alzheimer’s Disease at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2025

GlobeNewswire

Dec. 3, 2025

Mesa Laboratories, Inc. to Announce Third Quarter Results on February 3, 2026

GlobeNewswire

Dec. 3, 2025

The New England Journal of Medicine Publishes Positive Phase 3 VALIANT Results of EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN

GlobeNewswire

Dec. 3, 2025

Announcement relating to despatch of Definitive Proxy Statement and details of Scheme Meeting and Extraordinary General Meeting

GlobeNewswire

Dec. 3, 2025

Mural Oncology Announces Sanction of the Scheme by the High Court

GlobeNewswire

Dec. 3, 2025

Picard Medical, Inc. and SynCardia Systems LLC CEO to Present at CSI Focus D-HF 2025 in Frankfurt, Germany

GlobeNewswire

Dec. 3, 2025

Supernus Pharmaceuticals to Participate in the Bank of America Securities 2025 CNS Therapeutics Virtual Conference

GlobeNewswire

Dec. 3, 2025

Soleno Therapeutics Announces the Passing of Board Member William G. Harris

GlobeNewswire

Dec. 3, 2025

TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Future Market Opportunities

GlobeNewswire

Dec. 3, 2025

Inotiv Reports Fourth Quarter and Full Year Financial Results for Fiscal 2025 and Provides Business Update

GlobeNewswire

Dec. 3, 2025

ORIC® Pharmaceuticals Announces Enozertinib (ORIC-114) Late-Breaking Oral Presentations in EGFR Atypical and EGFR exon 20 NSCLC at the ESMO Asia Congress 2025

GlobeNewswire

Dec. 3, 2025

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire

Dec. 3, 2025

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

Dec. 3, 2025

HealthEquity Reports Third Quarter Ended October 31, 2025 Financial Results

GlobeNewswire

Dec. 3, 2025

Sickle Cell Disease Market is Predicted to Exhibit Remarkable Growth at a CAGR of 22.1% During the Forecast Period (2025–2034) Across 6MM, Owing to the Increasing Prevalence, Awareness, and Advancements in Gene Therapies | DelveInsight

GlobeNewswire

Dec. 3, 2025

Most Popular Legal Steroids for Muscle Building from CrazyBulk: Legal Steroid Alternatives for Lean Muscle Growth and Cutting in 2026

GlobeNewswire

Dec. 3, 2025

Novel Pharmaceutical Avextra Capsule Enhances Patient Experience and Treatment Acceptance

GlobeNewswire

Dec. 3, 2025

Neue Avextra-Kapsel verbessert Therapieerfahrung und Akzeptanz der Behandlung seitens der Patienten

GlobeNewswire

Dec. 3, 2025

Cosmos Health Launches Strategic Partnership With Prime Ledger to Transform $300M Treasury and Tokenize IP Assets

GlobeNewswire